Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 1/20 | 0.48 |
| ▸ | GABRD | O14764 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.48 |
| ▸ | GABRE | P78334 | 1/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.48 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.48 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.48 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.48 |
| ▸ | AHR | P35869 | 3/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16720622 | 0.85 | MEN1 (0.46) | AHRCYP2A6ALOX15USP2MAPT | |
| SCHEMBL20110716 | 0.77 | GABRP (0.42) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL18188316 | 0.72 | GABRP (0.39) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL16720176 | 0.72 | NPC1 (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL30138435 | 0.71 | AHR (0.56) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL30882 | 0.71 | AHR (0.56) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6195484 | 0.71 | KDM4E (0.51) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL18188405 | 0.71 | GABRP (0.40) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL8404071 | 0.70 | GABRP (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3340549 | 0.70 | LTA4H (0.48) | AHRNR4A2CYP2A6ALOX15F7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101247853-B | Substituted indole compounds having NOS inhibitory activity | NEURAXON INC | 2014-11-12 | — | — | CN | disclosed |
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-02-20 | — | — | US | disclosed |
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-02-20 | — | — | US | disclosed |
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-02-20 | — | — | US | disclosed |
| US-8586620-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-11-19 | — | — | US | disclosed |
| US-8586620-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-11-19 | — | — | US | disclosed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | disclosed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | disclosed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | disclosed |
| US-7951940-B2 | neuronal nitric oxide synthase (nNOS) isoform inhibitors; 2-ethyl-1-(1H-indol-5-yl)-isothiourea; neurogenerative disorders, stroke, reperfusion injury, head trauma, migraine headache, neuropathic pain, drug abuse, hyperalgesia | NEURAXON, INC. (CA) | 2011-05-31 | — | — | US | disclosed |
| WO-2007063418-A2 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2007-06-07 | — | — | WO | disclosed |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NEURAXON INC. (CA) | 2006-11-16 | — | — | US | disclosed |
| EP-0666858-B1 | 5-ARYLINDOLE DERIVATIVES AND THEIR USE AS SEROTONIN (5-HT 1) AGONISTS | PFIZER (US) | 2001-06-13 | — | — | EP | disclosed |
| EP-1094064-A1 | 5-arylindolederivatives and their use as serotonin(5-ht1)agonists | PFIZER INC. (US) | 2001-04-25 | — | — | EP | disclosed |
| CN-1051313-C | 5-arylindole derivatives | PFIZER (US) | 2000-04-12 | — | — | CN | disclosed |
| CN-1045294-C | Indole derivatives | PFIZER (US) | 1999-09-29 | — | — | CN | disclosed |
| US-5886008-A | 5-arylindole derivatives | PFIZER INC. (US) | 1999-03-23 | — | — | US | disclosed |
| US-5639752-A | SEROTONIN AGONIST | PFIZER INC (US) | 1997-06-17 | — | — | US | disclosed |
| CN-1094727-A | The 5-(hetero) aryl indole derivatives | PFIZER (US) | 1994-11-09 | — | — | CN | disclosed |
| CN-1072679-A | INDOLE DERIVATIVES | PFIZER (US) | 1993-06-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | GABRP 140/4885GABRD 2516/4885GABRA1 1682/4885 |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NOS2, NOS1, NOS3 | GABRP 140/4885GABRD 2516/4885GABRA1 1682/4885 |
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | GABRP 140/4885GABRD 2516/4885GABRA1 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.